Evidence map›Paper›PMID 36778498›Full record

ArticlebioRxiv : the preprint server for biology2023

FDX1 regulates cellular protein lipoylation through direct binding to LIAS.

Margaret B Dreishpoon, Nolan R Bick, Boryana Petrova, Douglas M Warui, Alison Cameron, Squire J Booker, Naama Kanarek, Todd R Golub, Peter Tsvetkov

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 25 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Margaret B DreishpoonBroad Institute of Harvard and MIT, Cambridge, USA.
Nolan R BickBroad Institute of Harvard and MIT, Cambridge, USA.
Boryana PetrovaHarvard Medical School, Boston, MA, USA.
Douglas M WaruiDepartment of Chemistry and Biochemistry and Molecular Biology and the Howard Hughes Medical Institute, The Pennsylvania State University, PA, United States.
Alison CameronBroad Institute of Harvard and MIT, Cambridge, USA.
Squire J BookerDepartment of Chemistry and Biochemistry and Molecular Biology and the Howard Hughes Medical Institute, The Pennsylvania State University, PA, United States.
Naama KanarekBroad Institute of Harvard and MIT, Cambridge, USA.
Todd R GolubBroad Institute of Harvard and MIT, Cambridge, USA.
Peter TsvetkovBroad Institute of Harvard and MIT, Cambridge, USA.
Broad Institute · USPennsylvania State University · USBoston Children's Hospital · US

Funding

Making cancer precision medicine real: bottlenecks and opportunitiesR35CA242457 · NCI · BROAD INSTITUTE, INC. · PI GOLUB, TODD R. · 2019 to 2025
$6.9M
Radical Mechanisms of Iron-Sulfur ProteinsR35GM122595 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI SQUIRE J. BOOKER · 2017 to 2026
$3.4M
NCI NIH HHS R35 CA242457NIGMS NIH HHS R35 GM122595
6 · The paper itself

Abstract

Ferredoxins are a family of iron-sulfur (Fe-S) cluster proteins that serve as essential electron donors in numerous cellular processes that are conserved through evolution. The promiscuous nature of ferredoxins as electron donors enables them to participate in many metabolic processes including steroid, heme, vitamin D and Fe-S cluster biosynthesis in different organisms. However, the unique natural function(s) of each of the two human ferredoxins (FDX1 and FDX2) are still poorly characterized. We recently reported that FDX1 is both a crucial regulator of copper ionophore induced cell death and serves as an upstream regulator of cellular protein lipoylation, a mitochondrial lipid-based post translational modification naturally occurring on four mitochondrial enzymes that are crucial for TCA cycle function. Here we show that FDX1 regulates protein lipoylation by directly binding to the lipoyl synthase (LIAS) enzyme and not through indirect regulation of cellular Fe-S cluster biosynthesis. Metabolite profiling revealed that the predominant cellular metabolic outcome of FDX1 loss-of-function is manifested through the regulation of the four lipoylation-dependent enzymes ultimately resulting in loss of cellular respiration and sensitivity to mild glucose starvation. Transcriptional profiling of cells growing in either normal or low glucose conditions established that FDX1 loss-of-function results in the induction of both compensatory metabolism related genes and the integrated stress response, consistent with our findings that FDX1 loss-of-functions is conditionally lethal. Together, our findings establish that FDX1 directly engages with LIAS, promoting cellular protein lipoylation, a process essential in maintaining cell viability under low glucose conditions.

Identifiers

PMID36778498
PMCPMC9915701
OpenAlexW4319225475

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.